Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
+0.60 (1.65%)
At close: May 24, 2024, 4:00 PM
-0.75 (-2.03%)
After-hours: May 24, 2024, 7:30 PM EDT

Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.

Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.

It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc.
Celldex Therapeutics logo
Country United States
IPO Date Mar 10, 2008
Industry Biotechnology
Sector Healthcare
Employees 160
CEO Anthony S. Marucci M.B.A.

Contact Details

53 Frontage Road, Suite 220
Hampton, New Jersey 08827
United States
Phone 908-200-7500
Website celldex.com

Stock Details

Ticker Symbol CLDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000744218
CUSIP Number 15117B202
ISIN Number US15117B2025
Employer ID 13-3191702
SIC Code 2835

Key Executives

Name Position
Anthony S. Marucci M.B.A. Founder, President, Chief Executive Officer and Director
Dr. Tibor Keler Founder, Chief Scientific Officer and Executive Vice President
Sam Martin Senior Vice President, Chief Financial Officer, Secretary and Treasurer
Dr. Margo Heath-Chiozzi M.D. Senior Vice President of Regulatory Affairs
Dr. Diane C. Young M.D. Senior Vice President and Chief Medical Officer
Prof. Joseph P. Schlessinger Ph.D. Co-Founder and Member of Scientific Advisory Board
Sarah Cavanaugh Senior Vice President of Corporate Affairs and Administration
Patrick Till Senior Director of Investor Relations and Corporate Communications
Freddy A. Jimenez Esq. Senior Vice President and General Counsel
Dr. Ronald A. Pepin Chief Business Officer and Senior Vice President

Latest SEC Filings

Date Type Title
May 6, 2024 10-Q Quarterly Report
May 6, 2024 8-K Current Report
Apr 25, 2024 ARS Filing
Apr 25, 2024 DEF 14A Other definitive proxy statements
Mar 1, 2024 8-K Current Report
Mar 1, 2024 424B5 Filing
Feb 28, 2024 424B5 Filing
Feb 26, 2024 424B5 Filing
Feb 26, 2024 10-K Annual Report
Feb 26, 2024 8-K Current Report